trial
began
knowledg
publish
report
robust
clinic
studi
safeti
andor
efficaci
chloroquin
cq
andor
hydroxychloroquin
hcq
treatment
recent
pandem
search
pubm
also
medrxivorg
preprint
server
health
scienc
without
peer
review
without
languag
restrict
includ
chines
public
studi
publish
dec
april
use
search
term
coronaviru
found
three
nonrandom
studi
limit
sampl
size
larger
patient
popul
found
higher
dosag
cq
day
present
toxic
red
flag
particularli
affect
qtc
prolong
limit
sampl
size
recruit
far
allow
show
benefit
regard
treatment
efficaci
howev
higher
fatal
associ
higher
dosag
day
followup
result
prematur
halt
arm
first
doubleblind
random
clinic
trial
address
differ
dosag
cq
treatment
sever
patient
absenc
control
group
use
placebo
due
imposs
use
drug
recommend
nation
level
use
histor
data
literatur
infer
comparison
lethal
endpoint
followup
day
ongo
larger
sampl
size
longterm
lethal
better
estim
preliminari
find
trial
suggest
higher
dosag
cq
g
total
dose
day
recommend
safeti
concern
regard
qtc
prolong
increas
lethal
brazilian
popul
often
older
patient
use
drug
azithromycin
oseltamivir
also
prolong
qtc
interv
among
patient
random
lower
dosag
group
day
treatment
total
dose
g
given
limit
number
patient
far
enrol
still
possibl
estim
clear
benefit
cq
patient
sever
ard
preliminari
data
viral
clearanc
respiratori
secret
confirm
case
also
indic
littl
effect
drug
high
dosag
studi
initi
cq
prior
onset
sever
phase
diseas
urgent
need
specif
antivir
therapi
recommend
diseas
caus
recent
public
drawn
attent
possibl
benefit
chloroquin
cq
studi
aim
comprehens
evalu
safeti
efficaci
two
differ
cq
dosag
patient
establish
sever
perform
parallel
doubleblind
random
phase
iib
clinic
trial
aim
assess
safeti
efficaci
two
differ
cq
dosag
adjunct
therapi
hospit
patient
sar
manau
brazilian
amazon
elig
particip
alloc
receiv
oral
via
nasogastr
tube
high
dose
cq
cq
twice
daili
day
total
dose
low
dose
cq
day
twice
daili
first
day
total
dose
addit
patient
receiv
ceftriaxon
azithromycin
studi
regist
clinicaltrialsgov
number
predefin
patient
sampl
size
patient
enrol
high
dosag
cq
arm
present
qtc
trend
toward
higher
lethal
lower
dosag
fatal
rate
day
overlap
ci
histor
data
similar
patient
use
cq
patient
pair
sampl
respiratori
secret
day
neg
six
patient
preliminari
find
suggest
higher
cq
dosag
regimen
recommend
treatment
potenti
safeti
hazard
result
forc
us
prematur
halt
patient
recruit
arm
given
enorm
global
push
use
cq
result
one
found
trial
provid
robust
evid
updat
patient
manag
recommend
coronavirus
first
discov
famili
rna
virus
typic
caus
respiratori
intestin
infect
bird
mammal
human
coronavirus
often
caus
mild
upper
respiratori
tract
infect
togeth
rhinovirus
two
main
underli
aetiolog
normal
cold
sever
diseas
secondari
virus
usual
restrict
immunocompromis
individu
formerli
confin
hubei
provinc
rapidli
spread
mani
countri
compel
offici
declar
global
pandem
march
origin
viru
yet
fulli
elucid
genom
analysi
suggest
close
relat
virus
previous
identifi
bat
infect
appear
caus
wide
rang
symptom
encompass
asymptomat
infect
mild
infect
upper
respiratori
tract
sever
viral
pneumonia
respiratori
failur
multipl
organ
failur
death
previous
expect
studi
shown
detail
clinic
featur
patient
viral
pneumonia
pneumonia
laboratori
confirm
patient
china
critic
ill
almost
critic
patient
die
overal
rate
fatal
case
estim
tenfold
higher
observ
season
influenza
death
involv
older
adult
mani
underli
chronic
diseas
prolong
use
month
even
year
target
scenario
cq
may
deposit
mani
tissu
especi
eye
caus
retin
toxic
myopathi
also
associ
use
cq
major
complic
even
short
regimen
potenti
qtc
prolong
favor
fatal
arrhythmia
ventricular
tachycardia
torsad
de
point
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
day
inclus
day
inclus
patient
treat
combin
hcq
azithromycin
consid
virolog
cure
compar
patient
treat
hcq
alon
control
group
result
albeit
highli
preliminari
probabl
suffici
power
conclus
support
effort
evalu
thoroughli
effect
cq
evolut
prognosi
health
commiss
guangdong
provinc
recommend
use
cq
tablet
dose
mg
twice
daili
day
total
dose
treatment
patient
age
year
mild
moder
sever
pneumonia
secondari
long
specif
contraind
howev
guarante
adequ
patient
followup
strict
monitor
evalu
plan
safeti
efficaci
recommend
oppos
treatment
recommend
evalu
differ
studi
cdc
initi
recommend
adult
load
dose
consist
mg
cq
base
tablet
mg
follow
mg
h
day
mg
bid
given
oral
day
shorter
treatment
regimen
versu
day
would
potenti
reduc
side
effect
assum
drug
halflif
hour
fact
mani
countri
compassion
use
cq
hcq
alreadi
formal
indic
sever
patient
made
uneth
test
proper
efficaci
due
lack
placebo
arm
compar
studi
aim
comprehens
evalu
primarili
safeti
secondarili
efficaci
cq
two
differ
dosag
compar
histor
data
report
literatur
similar
sever
patient
receiv
cq
treatment
sever
respiratori
syndrom
caus
report
data
first
random
patient
studi
conduct
accord
principl
declar
helsinki
good
clinic
practic
guidelin
intern
confer
harmon
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
conep
approv
patient
andor
legal
repres
case
unconsci
inform
object
risk
particip
given
time
care
read
sign
inform
consent
form
icf
recoveri
patient
also
sign
icf
random
onlin
clinic
monitor
qualiti
control
perform
virtual
independ
data
safeti
monitor
board
dsmb
epidemiologist
clinician
expert
infecti
diseas
time
implement
review
protocol
daili
meet
followup
activ
studi
trial
report
accord
consolid
standard
report
trial
consort
statement
parallel
doubleblind
random
phase
iib
clinic
trial
start
march
rd
aim
assess
safeti
efficaci
cq
treatment
hospit
patient
sever
respiratori
syndrom
secondari
infect
manau
capit
amazona
state
biggest
brazilian
state
million
inhabit
scatter
ninth
largest
countri
subdivis
world
major
industri
academ
tourist
centr
amazon
region
sever
transport
hub
thousand
annual
foreign
visitor
mostli
serv
social
free
unifi
health
system
su
organ
health
assist
network
also
count
mani
privat
hospit
citi
also
count
variou
univers
graduat
program
tradit
clinic
research
group
dedic
studi
infecti
diseas
begin
studi
autochthon
transmiss
alreadi
record
studi
site
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
hospit
patient
age
year
older
time
inclus
respiratori
rate
higher
rpm
andor
heart
rate
higher
bpm
absenc
fever
andor
peripher
oxygen
satur
lower
ambient
air
andor
shock
defin
mean
arteri
pressur
lower
mmhg
need
vasopressor
medicin
oliguria
lower
level
conscious
includ
children
year
age
includ
due
known
lower
morbiditymort
patient
enrol
laboratori
confirm
consid
procedur
could
delay
random
analys
point
patient
includ
regardless
confirm
etiolog
safeti
issu
focu
manuscript
issu
flowchart
studi
present
clinicalepidemiolog
suspect
case
case
alreadi
confirm
rtpcr
sampl
primari
outcom
reduct
lethal
calcul
assum
lethal
incid
critic
ill
patient
use
cq
histor
control
arm
cq
would
equal
abl
reduc
lethal
least
thu
consid
test
differ
proport
group
size
power
alpha
particip
need
per
group
ad
loss
final
sampl
particip
obtain
sampl
calcul
perform
r
statist
packag
function
implement
trialsiz
gsdesign
packag
intervent
test
studi
base
differ
regimen
use
cq
tablet
farmanguinho
fiocruz
brazil
elig
particip
alloc
ratio
receiv
oral
via
nasogastr
tube
case
orotrach
intub
either
high
dosag
cq
cq
tablet
twice
daili
day
total
dose
b
low
dosag
cq
cq
tablet
placebo
twice
daili
day
tablet
placebo
tablet
follow
placebo
tablet
placebo
tablet
twice
daili
total
dose
placebo
tablet
also
produc
farmanguinho
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
use
latter
order
standard
treatment
blind
research
team
particip
per
hospit
protocol
patient
meet
criteria
studi
ard
use
intraven
ceftriaxon
day
plu
azithromycin
day
systemat
start
day
oseltamivir
day
also
prescrib
influenza
infect
suspect
amazon
ongo
flu
season
januaryapril
clinic
paramet
measur
daili
routin
clinic
staff
day
discharg
death
day
discharg
patient
assess
efficaci
safeti
outcom
laboratori
paramet
ecg
perform
whenev
need
clinic
discret
data
record
medview
transfer
electron
databas
redcap
tablet
comput
bedsid
ward
valid
extern
trial
monitor
staff
safeti
outcom
includ
advers
event
ae
occur
treatment
seriou
advers
event
sae
prematur
temporari
discontinu
treatment
advers
event
classifi
accord
nation
cancer
institut
common
terminolog
criteria
advers
event
work
hypothesi
around
trial
design
halv
mortal
group
day
thu
primari
endpoint
mortal
electron
gener
random
list
prepar
independ
statistician
four
block
particip
per
block
random
list
associ
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
patient
studi
number
opaqu
surfac
hide
treatment
group
design
list
access
nonblind
pharmacist
studi
attempt
minim
observ
bia
particip
random
studi
pharmacist
design
treatment
regimen
time
inclus
subsequ
identifi
throughout
studi
alloc
studi
number
alway
assign
follow
chronolog
order
case
sae
unmask
avail
dsmb
member
preliminari
analys
perform
even
schedul
interim
analys
order
guid
earli
halt
cq
arm
hematolog
biochemistri
analys
perform
automat
machin
sampl
assay
specimen
consid
posit
viral
target
show
ct
lower
quantit
rtpcr
data
present
swab
specimen
collect
intentiontotreat
analysi
conduct
part
primari
safeti
efficaci
analysi
untaken
mistaken
tablet
dosag
correct
pend
renal
liver
failur
systemat
regist
daili
allow
therefor
per
protocol
analysi
descript
statist
use
demograph
laboratori
clinic
data
assess
safeti
high
low
dosag
cq
proport
ci
death
group
compar
histor
proport
ci
death
patient
use
cq
countri
qualit
variabl
chisquar
test
fisher
exact
test
perform
ttest
mannwhitney
test
use
meansmedian
comparison
accumul
proport
detect
assess
surviv
model
use
kaplanmei
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
estim
curv
logrank
petopeto
correct
low
observ
number
end
followup
test
use
surviv
time
event
analys
statist
analys
perform
r
statist
packag
p
consid
signific
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
studi
site
patient
random
per
protocol
older
patient
age
enrol
high
dosag
cq
arm
tabl
characterist
similar
age
group
allow
proper
comparison
histori
heart
diseas
frequent
among
patient
receiv
higher
cq
dosag
occurr
myocard
defin
ckmb
higher
upper
normal
limit
may
final
complic
sever
sepsi
lesion
trigger
viru
seen
patient
patientarm
echocardiogram
perform
time
one
patient
develop
sever
rhabdomyolysi
causal
could
attribut
viru
cq
alreadi
known
caus
myolysi
tabl
two
patient
high
dosag
cq
arm
evolv
ventricular
tachycardia
death
sever
type
arrythmia
usual
facilit
qtc
prolong
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
http
doi
medrxiv
preprint
differ
hematolog
renal
toxic
seen
group
patient
pair
sampl
arm
respiratori
secret
day
neg
six
patient
fatal
rate
sampl
therefor
still
overlap
ci
metaanalysi
base
two
major
studi
use
similar
patient
without
cq
surviv
per
arm
present
comparison
histor
collat
avail
data
two
similar
lethal
studi
patient
receiv
cq
figur
arm
similar
data
show
clear
differ
despit
death
higher
dosag
cq
arm
subgroup
analys
criticallyil
patient
enrol
compar
larg
histor
samples
cohort
patient
lombardi
itali
figur
differ
seen
group
fatal
seem
higher
itali
patient
use
cq
two
death
older
yearsold
nineteen
death
virolog
confirm
antemortem
base
find
dsmb
recommend
immedi
interrupt
high
dosag
arm
patient
unmask
revert
low
dosag
arm
per
protocol
analysi
perform
due
imposs
monitor
drug
administr
twice
day
hospit
radiolog
find
present
manuscript
baselin
due
inabl
perform
care
analys
avail
ct
scan
time
radiolog
complet
efficaci
data
present
later
uniqu
pandem
situat
health
profession
choos
offer
medic
assist
gener
report
reliabl
data
dichotomi
compromis
gener
good
qualiti
evid
clinic
manag
global
recommend
made
base
unpow
studi
howev
due
chaotic
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
urgenc
drug
prescrib
compassion
manner
given
sever
diseas
howev
cq
despit
safe
drug
use
year
malaria
might
toxic
dosag
recommend
chines
author
high
dosag
day
studi
rais
enough
red
flag
stop
use
dosag
cq
total
day
due
present
cq
tablet
farmanguinho
worldwid
order
avoid
unnecessari
death
abl
independ
assess
toxic
role
azithromycin
patient
alreadi
use
antibiot
per
hospit
protocol
oseltamivir
also
increas
qtc
could
potenti
cardiac
side
effect
patient
also
use
drug
suspect
influenza
infect
ethic
imposs
use
placebo
arm
compel
use
histor
data
base
similar
patient
use
cq
fatal
rate
observ
lower
howev
one
reliabl
conclud
cq
benefit
placebocontrol
studi
perform
countri
routin
use
drug
sever
ongo
trial
includ
ii
trial
group
clinicaltrialsgov
number
also
address
earli
use
cq
antiinflammatori
properti
could
potenti
help
inform
urgent
need
placebocontrol
doubleblind
random
trial
addit
help
patient
improv
cq
could
use
decreas
viral
load
respiratori
secret
allow
less
nosocomi
postdischarg
transmiss
howev
data
provid
evid
effect
patient
use
cq
irrespect
dosag
fail
present
evid
substanti
viral
clearanc
fifth
day
day
posit
rtpcr
even
concomit
use
azithromycin
cq
recommend
treatment
malaria
particular
due
low
cost
dose
result
safe
concentr
need
treat
diseas
cq
deposit
tissu
especi
eye
caus
retin
toxic
associ
prolong
use
qtc
prolong
seen
patient
similar
report
patient
use
hcq
differ
seen
arm
therefor
suggest
lethal
attribut
higher
dosag
could
caus
cardiotox
myopathi
also
associ
cq
use
studi
one
patient
develop
rhabdomyolysi
attribut
cq
drug
withdrawn
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
two
patient
myocard
suspect
base
ckmb
elev
sinc
first
day
hospit
suggest
myocard
relat
case
drug
prolong
qtc
could
lead
sever
arrhythmia
unfortun
studi
random
probabl
due
low
sampl
size
assign
older
patient
heart
diseas
high
dosag
arm
therefor
one
limit
conclus
studi
lethal
per
arm
high
cq
dosag
arm
present
patient
prone
cardiac
complic
without
cq
case
use
cq
elderli
heart
diseas
made
caution
lethal
criticallyil
patient
seem
even
higher
similar
patient
itali
could
reflect
qualiti
icu
countri
possibl
lack
deleteri
effect
cq
patient
occurr
myocard
sampl
togeth
confirm
qtc
prolong
warrant
caution
relat
drug
safeti
particularli
consid
eventu
increas
fatal
arrythmia
ventricular
tachycardia
studi
strength
doubleblind
perform
public
hospit
repres
case
countri
like
brazil
compliant
good
clinic
practic
vigil
highli
involv
dsmb
assess
two
dose
scheme
cq
first
time
patient
major
limit
howev
includ
one
singl
center
use
placebo
control
group
use
placebo
brazil
sever
case
infect
consid
ethic
accept
nation
regulatori
health
agenc
especi
due
compassion
use
cq
earli
report
seem
indic
effect
vitro
vivo
conclus
high
cq
dosag
scheme
given
day
suffici
safe
warrant
continu
particular
studi
arm
therefor
strongli
recommend
dosag
longer
use
anywher
treatment
sever
especi
real
world
older
patient
use
cardiotox
drug
rule
appar
benefit
cq
seen
regard
lethal
patient
far
still
enrol
patient
low
cq
dose
group
complet
origin
plan
sampl
size
order
better
understand
role
cq
hcq
recommend
follow
next
step
trial
evalu
role
prophylact
drug
trial
evalu
efficaci
progress
sever
administ
patient
mildmoder
diseas
even
fail
gener
good
evid
time
control
current
pandem
inform
highli
impact
way
deal
next
coronaviru
outbreak
futur
studi
includ
data
safeti
monitor
board
dsmb
compos
gasr
qb
bca
ctdr
cjf
given
involv
day
day
review
activ
trial
close
monitor
safeti
event
role
decis
halt
studi
account
safeti
issu
studi
pi
decid
invit
individu
basi
coauthor
manuscript
member
dsmb
agre
includ
variabl
patient
unconsci
allow
complet
person
histori
data
collect
shown
decreas
hemoglobin
level
g
per
decilit
baselin
shown
increas
serum
level
baselin
sever
advers
event
relat
trial
regimen
prolong
qt
interv
correct
heart
rate
accord
fridericia
formula
qtcf
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
